Abstract | BACKGROUND: METHODS: In this phase I study, vinflunine was administered to patients with advanced malignancies as hard capsules given twice a day on days 1-2 every week, with 3 weeks cycles. Serial blood samples were collected during the first cycle for pharmacokinetic investigations. RESULTS: Thirty-six patients (pts) were treated at 6 dose levels 150 (3 pts), 190 (3 pts), 230 (8 pts), 300 mg/day (6 pts) and then 250 (3 pts) and 270 mg/day (13 pts). The Maximal Tolerated Dose (MTD) was reached at 300 mg/day where 2 patients out of 6 experienced a dose limiting toxicity ( febrile neutropenia with diarrhea). The lower dose level of 270 mg/day was the recommended dose (RD), the toxicity profile being mainly anaemia, neutropenia, fatigue and constipation. The pharmacokinetic analysis demonstrated the adequacy of the flat-fixed dosing regimen, as no correlation between clearance of vinflunine and body surface area was evidenced. Blood concentrations and exposure increased with dose, and a pharmacokinetic accumulation was observed, which is consistent with the terminal half-life of the compounds. The inter-individual exposure variability at the RD was 35%. CONCLUSION: Repeated weekly administration of oral vinflunine is feasible and exhibits a moderate inter-individual PK variability. The MTD was achieved at 300 mg/day given for 2 consecutive days. According to the protocol rules, the RD was established at 270 mg/day.
|
Authors | E Calvo, J B Vermorken, S Hiret, J Rodon, J Cortes, H Senellart, J Van den Brande, J Dyck, A Pétain, P Ferre, J Bennouna |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 69
Issue 6
Pg. 1467-75
(Jun 2012)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 22382883
(Publication Type: Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- Capsules
- Tubulin Modulators
- vinflunine
- Vinblastine
|
Topics |
- Adult
- Aged
- Capsules
- Drug Administration Schedule
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Metastasis
- Neoplasms
(drug therapy, pathology)
- Tubulin Modulators
(administration & dosage)
- Vinblastine
(administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics)
|